Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
5698593 | Clinical Oncology | 2014 | 7 Pages |
Abstract
The use of a hypofractionated IMRT boost after WPRT may allow a minimally invasive dose escalation to successfully treat patients with non-metastatic prostate cancer at high risk of lymph node involvement. Higher prostate-specific antigen values before radiotherapy may require alternative adjuvant treatments to further optimise the outcome of this high-risk group of patients.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
T. Zilli, S. Jorcano, L. Escudé, D. Linero, M. Rouzaud, A. Dubouloz, R. Miralbell,